Was kann die kardiale MR-Bildgebung heute leisten?

Seit ihren Anfängen vor 30 Jahren hat die Magnetresonanz (MR)-Bildgebung des Herzens enorme Fortschritte gemacht – mittlerweile gilt sie als Routinewerkzeug innerhalb der kardialen Diagnostik. Neben ihrer Überlegenheit bei der Bestimmung von Masse und Volumen des Herzens ist die strukturelle Darstellung des Herzmuskelgewebes zur Domäne der kardialen MR-Bildgebung geworden. Dieser Beitrag stellt eine Auswahl aktueller Anwendungen vor.

Abstract

Since its beginning, 30 years ago, magnetic resonance imaging of the heart made tremendous progress. Starting from an almost experimental level in the 90 s it has now become a routine tool within cardiac diagnostics. This article presents a selection of present applications of cardiac magnetic resonance imaging. Besides it superiority in determining mass and volumes of the heart, structural imaging of myocardial tissue has become the domain of cardiac magnetic resonance imaging. This implies detection and quantification of scars and fibrosis, inflammatory and infiltrative processes in myocarditis and amyloidosis, and characterization of cardiac tumors. Perfusion imaging allows detection of ischemia, and measurement of blood flow quantifies cardiac shunts and valve disorders. In combination with Positron Emission Tomography, the relationship of molecular/cellular processes and functional, microstructural alterations become visible in myocarditis and amyloidosis. Recent contraindications of cMRI/MRI as cardiac devices MRI have been resolved; however, image quality of the heart is still a challenge.

Schlüsselwörter

kardiale Magnetresonanz-Bildgebung - Fibrose - Narbe - Myokarditis - Amyloidose

Key words

cardiac magnetic resonance imaging - fibrosis - scar - myocarditis - amyloidosis

Publication History

Article published online:
01 March 2021

• Literatur

• 1 Oppelt A, Graumann R, Barfuss H. et al. FISP: eine neue schnelle Pulssequenz für die Kernspintomografie. Electromedica 1986; 54: 15-18
• 2 Kim RJ, Wu E, Rafael A. et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343: 1445-1453
• 3 Myerson SG, Bellenge NG, Pennell DJ. Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension 2000; 39: 750-755
• 4 Friedrich MG, Sechtem U, Schulz-Menger J. et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 2009; 53: 1475-1487
• 5 Ferreira VM, Schulz-Menger J, Holmvang G. et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 2018; 72: 3158-3176
• 6 Messroghli DR, Radjenovic A, Kozerke S. et al. Modified Look‐Locker inversion recovery (MOLLI) for high‐resolution T1 mapping of the heart. Magn Reson Med 2004; 52: 141-146
• 7 Kampf T, Bauer WR, Reiter T. Improved post-processing strategy for MOLLI based tissue characterization allows application in patients with dyspnoe and impaired left ventricular function. Z Med Phys 2018; 28: 25-35
• 8 Parwani P, Ramesh T, Akhter N. et al. Differentiation of Cardiac Masses by Cardiac Magnetic Resonance Imaging. Curr Cardiovasc Imaging Rep 2020; 13: 1-12
• 9 Zhu D, Yin S, Cheng W. et al. Cardiac MRI-based multi-modality imaging in clinical decision-making: Preliminary assessment of a management algorithm for patients with suspected cardiac mass. Int J Cardiol Vessel 2016; 203: 474-481
• 10 Montalescot G, Sechtem U, Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003
• 11 Garg P, Swift AJ, Zhong L. et al. Assessment of mitral valve regurgitation by cardiovascular magnetic resonance imaging. Nat Rev Cardiol 2019; 17: 1-15
• 12 Lapa C, Reiter T, Li X. et al. Imaging of myocardial inflammation with somatostatin receptor based PET/CT—a comparison to cardiac MRI. Int J Cardiol Vessel 2015; 194: 44-49
• 13 Reiter T, Werner RA, Bauer WR. et al. Detection of cardiac sarcoidosis by macrophage-directed somatostatin receptor 2-based positron emission tomography/computed tomography. Eur Heart J 2015; 36: 2404
• 14 Kircher M, Ihne S, Brumberg J. et al. Detection of cardiac amyloidosis with ¹⁸F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imaging 2019; 46: 1407-1416
• 15 Sommer T, Bauer W, Fischbach K. et al. MR imaging in patients with cardiac pacemakers and implantable cardioverter defibrillators. Rofo 2017; 189: 204-217
• 16 von Knobelsdorff-Brenkenhoff F, Bauer WR, Deneke T. et al. Empfehlungen zu kardialen MRT-Untersuchungen bei Patienten mit Herzschrittmachern und implantierbaren Kardioverter-Defibrillatoren. Der Kardiologe 2019; 13: 75-86
• 17 Nordbeck P, Beer M, Köstler H. et al. Cardiac catheter ablation under real-time magnetic resonance guidance. Eur Heart J 2012; 33: 1977
• 18 Christa M, Weng AM, Geier B. et al. Increased myocardial sodium signal intensity in Conn’s syndrome detected by 23Na magnetic resonance imaging. Eur Heart J Cardiovasc Imaging 2019; 20: 263-270